Findings from the CREATE-X and KATERINE clinical trials demonstrated that post-surgical capecitabine and T-DM1, respectively, can improve prognosis in early-stage triple-negative and HER2-positive breast cancer patients when the disease persists after NACT [35, 36]. This evidence concerns the gene ERBB2 and breast carcinoma.